

Edgar Filing: AAR CORP - Form ARS

AAR CORP

Form ARS

September 06, 2011

This document was generated as part of a paper submission.

Please reference the Document Control Number 11008304 for access to the original document.

to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). Indicate by checkmark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

Edgar Filing: AAR CORP - Form ARS

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On July 5, 2017, Joel C. Barrish, Ph.D., the Executive Vice President and Chief Scientific Officer of Achillion Pharmaceuticals, Inc. (the Company), provided notice of his intention to resign from the Company. His resignation is effective July 14, 2017.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACHILLION PHARMACEUTICALS, INC.

Date: July 10, 2017

By: /s/ Mary Kay Fenton
Mary Kay Fenton
Executive Vice President and Chief Financial
Officer